Kimberly-Clark (KMB) Q3 2026 Earnings Call: Q&A Summary

Q: Dara Mohsenian from Morgan Stanley asked about the confidence in fiscal 2026 guidance, Q4 delivery assumptions, and the puts and takes for 2027 regarding dilution and synergies.

A: Michael Hsu outlined a three-stage integration plan of ready, set, and grow, emphasizing seamless operations. Nelson Urdaneta added that the company is on track with deal metrics, including synergy pacing and leverage targets, and noted that Q4 will benefit from easier year-over-year comparisons.

Q: Peter Grom from UBS asked about the health of the North America business, specifically regarding share performance and pricing.

A: Michael Hsu attributed recent softness to retailer inventory changes and a postponed product launch, but noted strong performance in tissue. Nelson Urdaneta added that club distribution changes were a 1 point headwind, while tissue gained 20 basis points of share.

Q: Michael Lavery from Piper Sandler asked about Kenvue's brand health, how their brand-building framework compares, and the opportunity for top-line momentum.

A: Michael Hsu stated that Kenvue's challenges are primarily executional rather than structural. He highlighted positive momentum in OTC and baby brands and emphasized the need to improve creative execution in skincare and simplify oral care offerings.

Q: Chris Carey from Wells Fargo asked about the team's ability to deliver synergies while maintaining operational excellence and how leadership changes are being managed.

A: Michael Hsu expressed confidence in the leadership team and the new operating model. Nelson Urdaneta confirmed that 2027 dilution is relative to stand-alone Kimberly-Clark and noted that amortization will remain within non-GAAP metrics.

Q: Javier Escalante from Evercore asked about diaper performance in the U.S. and China, and how the company is using social commerce to build trust.

A: Michael Hsu noted that the diaper business is strong, with premiumization driving mix. Regarding China, he confirmed authorities cleared Huggies of safety allegations, and while recovery will take time, the team is focused on rebuilding consumer trust.

Q: Javier Escalante from Evercore asked for a simple narrative on the sequence of the synergy plan through 2027.

A: Michael Hsu noted that staffing changes will occur throughout 2027. Nelson Urdaneta detailed the $1.9 billion cost synergy plan, which is split between overhead optimization, cost of goods sold, and sales, marketing, and trade spend.

Q: Anna Lizzul from Bank of America asked about the Big Dreams diaper launch and how to think about freight cost headwinds.

A: Michael Hsu highlighted the Big Dreams launch as a value-oriented offering. Nelson Urdaneta projected $250 million in full-year gross inflation, largely driven by spot freight rates, and noted the Arbex joint venture is helping with cost containment.

Q: Robert Moskow from TD Cowen asked about the feasibility of revenue synergy targets and international expansion.

A: Michael Hsu clarified that revenue synergies are a flywheel play to reinvest in brands. Nelson Urdaneta clarified that the $1.9 billion synergy target is strictly cost-related, not revenue-related.

Q: Susan Anderson from Canaccord Genuity asked about the status of retailer inventories and if there are impacts similar to competitors.

A: Michael Hsu stated that retailer inventory levels are within normal ranges. Nelson Urdaneta added that inventory optimization will continue as service levels improve.